Institution Directory

Clinical trials at Weill Cornell Medicine

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 1:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

779

Shown on this page

Current sort

Live official records

Conditions: Hemophilia A
Interventions: SPK-8011QQ; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 6
States / cities: Orange, California • San Francisco, California • Vallejo, California + 3 more

Conditions: Eosinophilic Esophagitis
Interventions: Vonoprazan, Placebo; Drug
Lead sponsor: Phathom Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 41
States / cities: Little Rock, Arkansas • Chula Vista, California • Los Angeles, California + 35 more

Conditions: Non-hodgkin Lymphoma, Multiple Myeloma
Interventions: Audio Tasks; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Carboplatin, Computed Tomography, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Nab-paclitaxel, Personalized Synthetic Long Peptide Vaccine, Poly ICLC, Sacituzumab Govitecan, Tremelimumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 30
States / cities: Orange, California • Sacramento, California • Aurora, Colorado + 22 more

Conditions: Type I Achalasia, Type II Achalasia, EGJ Outflow Obstruction Without Spastic/Hypercontractile Features
Interventions: Standard Myotomy, Tailored Short Myotomy; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 16
States / cities: Scottsdale, Arizona • La Jolla, California • Denver, Colorado + 12 more

Conditions: Kidney Transplant Rejection
Interventions: Frexalimab, Tacrolimus, rabbit anti-thymocyte globulin, mycophenolate mofetil, mycophenolate sodium, methylprednisolone, prednisone; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 14
States / cities: San Francisco, California • Atlanta, Georgia • Hines, Illinois + 9 more

Conditions: Diabetes type2, Obesity
Interventions: RESET Liner, Sham; Device · Other
Lead sponsor: Morphic Medical Inc.; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 27
States / cities: Gilbert, Arizona • Tucson, Arizona • Washington D.C., District of Columbia + 22 more

Conditions: Coronavirus Disease (COVID-19)
Interventions: Molnupiravir, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 3,082 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 71
States / cities: Cullman, Alabama • Paradise Valley, Arizona • Phoenix, Arizona + 58 more

Conditions: Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Interventions: ELA026; Drug
Lead sponsor: Electra Therapeutics Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 11 more

Conditions: Hemorrhagic Stroke, Aneurysm, Intracranial, Saccular Aneurysm, Fusiform Aneurysm, Brain Aneurysm
Interventions: Flow diversion; Device
Lead sponsor: phenox Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 25
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 21 more

Conditions: Obesity, Overweight and/or Obesity, Overweight
Interventions: PF-08653944, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 954 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 35
States / cities: Canoga Park, California • Escondido, California • Modesto, California + 26 more

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Ziftomenib, Placebo, Venetoclax, Azacitidine (AZA), Daunorubicin, Cytarabine (Ara-C); Drug
Lead sponsor: Kura Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 44
States / cities: Gilbert, Arizona • Clovis, California • La Jolla, California + 37 more

About this Weill Cornell Medicine institution page

What this page lists: ClinicalTrials.gov records that list Weill Cornell Medicine in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Weill Cornell Medicine

Filter and sort this campus

Live official records

A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

PREcision MEDicine In Achalasia (PREMEDIA)

A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation

The RESET System Pivotal Clinical Trial (Protocol Revision K)

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

About this Weill Cornell Medicine institution page